Body Pharm Retatrutide 32mg

Body Pharm supplies the Retatrutide 32 mg pen for procurement for research purposes in Spain. It is a pre-filled injectable format of LY3437943, a triple agonist that binds to the GIP, GLP-1 and glucagon receptors and which, at the time of the last revision of this page (October 2026), had published phase 3 results (TRIUMPH-1) but still had no authorisation as a medicine [3][7]. This page deals with batch traceability, with how the receptor mechanisms compare with one another, and with the choice between the 32 mg format and the 64 mg format.

The 32 mg format with a dose dial is well suited to dose-escalation protocols in research: the dial sets the dose directly in milligrams. The phase 2 data published in 2023 reported a mean reduction in body weight of up to 24.2% at 48 weeks in the highest dose step (Jastreboff et al., NEJM 2023) [1]. The parameters on the certificate of analysis are confirmed against the quality-control data sheet that accompanies every batch. This product is sold solely for laboratory research purposes and is not authorised for use in people [4].

Retatrutide 32 pen: what you need to know

• Retatrutide is a triple agonist that binds to the GIP, GLP-1 and glucagon receptors at the same time, a mechanism that no incretin therapy authorised at present can offer
• The dosing protocol is 2 mg per week for 4 weeks, then 4 mg per week for 4 weeks and then 8 mg per week for 4 weeks, with a maximum dose of 12 mg per week; the pen sets each one of those steps directly in milligrams
• The 32 mg pen is a pre-filled multi-dose pen with a 3 ml cartridge, and the "32 mg" is the total peptide content of the unit
• Every unit is delivered with batch-traceability documentation, documentation of purity by HPLC and a certificate of analysis
• Retatrutide does not have authorisation as a medicine and is supplied solely for the purposes of laboratory research
• Orders within Spain are sent with tracking for a flat shipping fee and arrive within 3–5 working days; unopened goods can be returned within the following 14 days

What is retatrutide 32 mg?

Retatrutide is a synthetic peptide of 39 amino acids and a triple agonist that binds simultaneously to the GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon receptors. Eli Lilly developed it under the code LY3437943 [1][2][3]. The "32 mg" label refers to the total peptide content in the reservoir of the pre-filled pen, not to the dose of each individual administration. The dose dial is graduated directly in milligrams: the number that appears in the dose window is the dose that is delivered.

The compound is formulated for subcutaneous administration in research models and is supplied solely for the purposes of laboratory research. It is not authorised for use in people and, as of 2026, it does not have authorisation as a medicine [4].

Clinical context of the mechanism

The phase 2 data published in 2023 reported a mean reduction in body weight of up to 24.2% at 48 weeks among the participants in the highest retatrutide dose step [1]. These figures describe the clinical research programme run by Eli Lilly and are cited here solely in order to characterise the pharmacological profile of the molecule, not in order to describe Body Pharm's research product.

Researchers who are drawing up escalation protocols should combine this page with our retatrutide dosing and titration protocol and with the mechanism comparison retatrutide vs. semaglutide vs. tirzepatide.

Triple-receptor mechanism: GIP, GLP-1 and glucagon

Retatrutide is a 39-amino-acid peptide that activates the GLP-1, GIP and glucagon receptors all at the same time [1]. The GLP-1 arm contributes satiety and a delay in gastric emptying; the GIP arm, the action on the adipocyte; the glucagon arm, more hepatic lipid oxidation and more energy expenditure, which is the part that no dual agonist reproduces. The complete mechanism, the published evidence and the comparison with semaglutide and tirzepatide are set out in what is retatrutide; here the only thing that matters is what changes for the 32 mg format: the dial fixes each step of the protocol directly in milligrams.

Why the 32 mg pen format for research?

The 32 mg pen is the right option for the first steps of the protocol and for pilot studies in which the dose-response curves are still being established. It keeps waste down to a minimum. Choose the 64 mg variant when your protocol is already fixed and you want to cover a larger number of weeks without having to change pens.

The two pens are handled in exactly the same way: the dose is set in milligrams on the dial, and the only thing that changes is how long each unit lasts. At a dose of 2 mg per week, a 32 mg pen gives roughly 16 administrations; at 4 mg, eight; at 8 mg, four. The first two steps of the protocol — four weeks at 2 mg and four weeks at 4 mg — use up 24 mg, so a single 32 mg pen covers them without any need to add a second unit to the order. The dose range studied in the phase 2 trial ran from 1 mg to 12 mg over the course of 48 weeks [1]; those are figures from the published trial and not the regimen for this product.

Waste matters: a 64 mg pen that is left half-used at the end of a short protocol represents a greater loss than a 32 mg equivalent would. For laboratories that are validating a new standard operating procedure (SOP), ordering the 32 mg pen first and scaling up to 64 mg once the dose points have been confirmed is the procurement route with the least risk. Some teams worry about running short halfway through the protocol; the practical answer is to order a second 32 mg pen as a reserve rather than committing to a single 64 mg unit.

The complete titration ladder and the week-by-week allocation of doses are set out in our retatrutide dosing and titration protocol; consult it before you fix the quantity of your order.

Specification of the 32 mg pen

The pen sets every one of the doses in the protocol directly in milligrams, including the maximum dose of 12 mg per week. The complete ladder, together with the criteria for moving up a step, is in the retatrutide dosing and titration protocol.

Storage

Keep the pen at between 2 and 8 °C and protected from light. While it is unopened, it keeps for 24 months. Once it has been punctured for the first time, use it within a period of 12 months. If you do not have a fridge available, the pen will tolerate up to 30 days at room temperature, with a maximum of 30 °C. Let it come up to room temperature before injecting and do not freeze it. The expiry date of the batch is shown on its CoA [6].

Batch traceability and quality standards

Every Body Pharm Retatrutide 32 mg pen is delivered with batch-traceability documentation that links the unit to the filling operation it came from. In concrete terms, that means: a unique batch number on the body of the pen, a filling date and a batch record that an independent buyer can request and cross-check before entering the unit into a laboratory inventory system.

Our filling process follows the principles of EU GMP (good manufacturing practice) for sterile parenteral formats. In practice, that includes the following:

• Purity analysis of the active peptide by HPLC (high-performance liquid chromatography) before filling takes place
• Sterility and bioburden checks carried out on the finished cartridge
• Assignment of a batch number that links the analytical results to the corresponding production run

The specific purity percentages and the endotoxin limits that apply to the current batch should be confirmed with our quality-control team at the time of placing the order, and should not be inferred from a generic specification sheet.

What the delivery contains

The 32 mg pen is delivered in sealed pharmaceutical packaging with a tamper-evident seal. Before you enter the unit into storage, check the following three things:

• The seal on the outer box is intact
• The cap of the pen has not been damaged
• The batch number printed on the pen matches the one on the certificate of analysis that accompanies the shipment

Any discrepancy at all is grounds for placing the unit in quarantine and getting in touch with us directly. Procurement teams should take the transit time into account (generally 3–5 working days) when they plan the receipt of the goods and their storage at 2–8 °C.

Researchers who are compiling a comparative procurement file may need, in addition to this documentation, our retatrutide vs. semaglutide vs. tirzepatide review.

Ordering, shipping and returns in Spain

Orders for the Retatrutide 32 mg pen within Spain are sent with tracking for a flat shipping fee and generally arrive within a period of 3–5 working days from dispatch. Purchasing managers who place grouped orders against a single order number can ask us by email for a consolidated shipping confirmation before the goods leave our warehouse.

The outer packaging is plain and unbranded, with no reference to peptides or to pharmaceutical products anywhere on the label. The description of the shipment in the tracking notifications and on card statements is kept generic, so that goods-in teams and finance departments see a neutral entry rather than the name of a product. Every shipment can be followed from start to finish by means of the tracking number communicated at the time of dispatch.

Returns of unused and unopened goods are accepted within the 14 days following delivery, provided that the tamper-evident seal and the outer box are intact. Pens that have been used or opened cannot be returned, for reasons of sterility and of chain of custody. All units are supplied solely for the purposes of laboratory research and are not intended for use in people or in animals; this is confirmed once again at the checkout stage. Researchers who are drawing up a study plan in parallel with the order should have our retatrutide dosing and titration protocol to hand before the shipment arrives.

Research use only: regulatory context

Body Pharm's Retatrutide 32 mg pen is supplied solely for in vitro research and analytical purposes. It is not intended for human consumption, nor for administration to animals, nor for diagnostic or therapeutic applications. This statement is repeated on the product label, at checkout and in the shipping documentation of every consignment.

As of 2026, retatrutide has no authorisation as a medicine [4]. Eli Lilly's phase 3 TRIUMPH-1 trial of retatrutide (LY3437943; NCT05929066) was completed in 2026 and its results were published in NEJM in September 2026 [3][7]. Purchasing managers should check the current authorisation status directly before preparing institutional documentation, because the regulatory situation can change quickly now that the phase 3 data are published.

Research peptides belong to a category that is separate from that of authorised medicines. Supply for the purposes of laboratory research does not provide a basis for any medical claim or for any suitability for exposure in people. We make no therapeutic, diagnostic or efficacy claims about the 32 mg pen, and none should be inferred from the explanation of the receptor mechanism that appears in other parts of this page.

Before placing an order, researchers should obtain approval for the material from their institution's ethics committee, a risk assessment for hazardous substances and the local biosafety guidelines. Teams that are planning a comparative protocol will find useful context for study design in our retatrutide vs. semaglutide vs. tirzepatide review.

Retatrutide 32 mg vs. 64 mg: which variant should you order?

Order the 32 mg pen for the start of the protocol, for dose-finding work and for short pilot runs. Order the 64 mg pen for established, high-volume studies in which the titration curve has already been fixed and the total cost per mg of peptide matters more than the flexibility of the format does.

The decision depends on the total peptide content and on the number of administrations that a single pen can cover before it is discarded. At a research dose point of 2 mg, a 32 mg pen gives roughly 16 administrations; at 4 mg, eight. The 64 mg pen doubles those figures, which is why it is often used in multi-arm protocols or in protocols of extended duration.

Check the current price in euros on the relevant product page before you place an order, since the cost per mg changes from one promotional cycle to the next. The companion titration guidance is in our guide to the retatrutide dosing and titration protocol.

More resources on peptide research

If you are putting together a wider set of incretin research around the 32 mg pen, four complementary resources on the Body Pharm site cover the adjacent topics.

Start with our retatrutide dosing and titration protocol for the step-up scheme that fits a 32 mg pen in an early phase of the work. The retatrutide vs. semaglutide vs. tirzepatide comparison explains the differences in receptor targets between mono-agonists, dual agonists and triple agonists, so that purchasing managers can justify the choice of format in writing. For adjacent compounds, see the weight-loss peptides category. The complete index of research guides brings together all of the protocols, mechanism explanations and handling notes that we publish.

Frequently Asked Questions

As of 2026, retatrutide falls into an exclusively research category because it has no authorisation as a medicine, although the first phase 3 results have now been published [3][4][7]. The following questions deal with the procurement, documentation and mechanism points that laboratory buyers in Spain raise with us most often.

Can retatrutide be bought in Spain for research purposes?

Body Pharm supplies retatrutide in Spain solely for in vitro research purposes. It is not authorised as a medicine; at the time of the last revision of this page (October 2026) it had published phase 3 results (TRIUMPH-1) but no marketing authorisation [3][4][7]. It cannot be delivered for, or used for, administration to people.

How many doses does the 32 mg pen contain?

The 32 mg pen contains 32 mg of retatrutide in total. The dose is set in milligrams on the dial, so the number of administrations you get depends on the dose: roughly 16 at 2 mg per week, eight at 4 mg and four at 8 mg. The complete protocol is in our retatrutide dosing and titration protocol.

Does Body Pharm ship retatrutide to any address in Spain?

Yes. We ship the 32 mg pen to any research address in Spain, with tracking and in packaging that is appropriate to the temperature; delivery generally takes place within a period of 3–5 working days. At present we ship only to addresses located in Spain.

What purity documentation accompanies each pen?

Every 32 mg pen is delivered with a batch-specific certificate of analysis that covers the identity of the peptide, the HPLC purity and the sterility parameters. The batch number printed on the pen label refers back to the CoA (certificate of analysis), so that you can confirm the analytical profile of the unit before entering it into the laboratory's inventory system.

Can I return an unused retatrutide pen?

Unopened pens with the tamper-evident seal still intact can be returned for inspection within the 14 days following delivery. Units that have been opened or that have been damaged by temperature cannot be taken back into stock in accordance with our quality policy for research material.

How does retatrutide differ from semaglutide?

Retatrutide is a triple agonist that acts on the GIP, GLP-1 and glucagon receptors, whereas semaglutide acts on the GLP-1 receptor alone [1][5]. The additional glucagon arm is associated with higher weight-loss endpoints, given that activation of the glucagon receptor increases energy expenditure. The 2023 phase 2 trial reported a mean loss of up to 24.2% at 48 weeks [1]. Read the full retatrutide vs. semaglutide vs. tirzepatide review.

Next steps

Settle the dose range and the duration of your protocol with our retatrutide dosing and titration protocol and then check the current price in euros on the product page. If your institution requires ethics or hazardous-substance approval before procurement, allow 5–10 working days for the internal authorisations. Once the approval is in place, you will usually receive your tracked order within a period of 3–5 working days. For grouped orders, or for questions about the availability of batches, send an email to our procurement team quoting your order reference.

Sources

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov/37366315
2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023. pubmed.ncbi.nlm.nih.gov/37385280
3. ClinicalTrials.gov, retatrutide trial registry (TRIUMPH phase 3 programme), consulted in October 2026. clinicaltrials.gov
4. EMA, list of medicines for human use authorised in the EU (EPAR). ema.europa.eu — consulted in October 2026 for the regulatory status of the compound.
5. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov/33567185
6. Body Pharm product specification: pre-filled multi-dose pen, 3 ml cartridge, dial in milligrams, storage at 2–8 °C, 24 months unopened and 12 months from first puncture, up to 30 days below 30 °C without refrigeration. Supplier specification, not a study.
7. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026. pubmed.ncbi.nlm.nih.gov/42814954